Magnesium in major depression

There are contradictory data regarding the levels of magnesium in patients with major depression (MD) and how antidepressants influence their concentration. Our results show erythrocyte magnesium in patients with MD (44.39 +/- 2.7 mg/L vs. 59.1 +/- 3.2 mg/L in control group, p < 0.05) and only in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Magnesium research 2009-09, Vol.22 (3), p.163S-166S
1. Verfasser: NECHIFOR, Mihai
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 166S
container_issue 3
container_start_page 163S
container_title Magnesium research
container_volume 22
creator NECHIFOR, Mihai
description There are contradictory data regarding the levels of magnesium in patients with major depression (MD) and how antidepressants influence their concentration. Our results show erythrocyte magnesium in patients with MD (44.39 +/- 2.7 mg/L vs. 59.1 +/- 3.2 mg/L in control group, p < 0.05) and only in patients with severe MD (Hamilton score > 23) was a moderate decrease in plasmatic magnesium observed (17.7 +/- 1.5 mg/L vs. 22.9 +/- 3.3 mg/L in control group). Therapy with antidepressants from different groups and with different mechanisms of action, such as amytriptiline (25 mg x 3/day per os, 4 weeks) and sertraline (50 mg x 3/day per os, 4 weeks) leads to a significant increase of magnesium concentration in erythrocytes (57.6 +/- 4.5 mg/L after amytriptiline, respectively 56.9 +/- 3.2 mg/L after sertraline, p < 0.05 vs. before therapy). At the same time, in patients with MD, plasmatic levels of zinc were significantly decreased before therapy and increased after treatment with amytriptiline and sertraline (0.68 +/- 0.09 mg/L before treatment vs. 0.9 +/- 0.07 after amytriptiline). There is a positive correlation between concentrations of magnesium in erythrocytes and the clinical evolution of patients with MD. We consider that increasing intracellular concentration is a component of the antidepressant mechanism of sertraline and amytriptiline and maybe of other antidepressants. Anhedonia and autolytic tendencies are important elements of MD symptomatology. We tested the influence of MgCl2 0.2 mM/kg/day on a reward system using conditioned place preference (Panlab) in rats. Our data show a moderate stimulation of the reward system by magnesium (290.6 +/- 27 s time spent in a conditioned compartment before magnesium treatment and 363.3 +/- 16 s after magnesium treatment) that reflects a stimulation of the reward system (RS). We consider that a magnesium-induced stimulation of the RS is an important issue for treating anhedonia in patients with MD. An increase of intracellular magnesium may be part of the mechanism of action of antidepressants.
doi_str_mv 10.1684/mrh.2009.0177
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1684_mrh_2009_0177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19780403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c290t-fa56b2dba191f70dd8f28fbf0b955015c01ca8fd15ed8b9535065439dbf8d7e33</originalsourceid><addsrcrecordid>eNpFz0tLw0AUhuFBFFurS5dKNi4Tz5lLMrOUUi9QcaPrMFdNaS7M2IX_3oQGXR04PHzwEnKNUGAp-X0bvwoKoArAqjohS1SC5hwonpIlKMFy5JQvyEVKOwAuaQXnZIGqksCBLcnNq_7sfGoObdZ0Wat3fcycH6JPqem7S3IW9D75q_muyMfj5n39nG_fnl7WD9vcUgXfedCiNNQZjQpDBc7JQGUwAYwSAlBYQKtlcCi8k-OPCSgFZ8qZIF3lGVuR_LhrY59S9KEeYtPq-FMj1FNmPWbWU2Y9ZY7-9uiHg2m9-9dz1wjuZqCT1fsQdWeb9OcoSskVE-wXbGhZ5w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Magnesium in major depression</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>NECHIFOR, Mihai</creator><creatorcontrib>NECHIFOR, Mihai</creatorcontrib><description>There are contradictory data regarding the levels of magnesium in patients with major depression (MD) and how antidepressants influence their concentration. Our results show erythrocyte magnesium in patients with MD (44.39 +/- 2.7 mg/L vs. 59.1 +/- 3.2 mg/L in control group, p &lt; 0.05) and only in patients with severe MD (Hamilton score &gt; 23) was a moderate decrease in plasmatic magnesium observed (17.7 +/- 1.5 mg/L vs. 22.9 +/- 3.3 mg/L in control group). Therapy with antidepressants from different groups and with different mechanisms of action, such as amytriptiline (25 mg x 3/day per os, 4 weeks) and sertraline (50 mg x 3/day per os, 4 weeks) leads to a significant increase of magnesium concentration in erythrocytes (57.6 +/- 4.5 mg/L after amytriptiline, respectively 56.9 +/- 3.2 mg/L after sertraline, p &lt; 0.05 vs. before therapy). At the same time, in patients with MD, plasmatic levels of zinc were significantly decreased before therapy and increased after treatment with amytriptiline and sertraline (0.68 +/- 0.09 mg/L before treatment vs. 0.9 +/- 0.07 after amytriptiline). There is a positive correlation between concentrations of magnesium in erythrocytes and the clinical evolution of patients with MD. We consider that increasing intracellular concentration is a component of the antidepressant mechanism of sertraline and amytriptiline and maybe of other antidepressants. Anhedonia and autolytic tendencies are important elements of MD symptomatology. We tested the influence of MgCl2 0.2 mM/kg/day on a reward system using conditioned place preference (Panlab) in rats. Our data show a moderate stimulation of the reward system by magnesium (290.6 +/- 27 s time spent in a conditioned compartment before magnesium treatment and 363.3 +/- 16 s after magnesium treatment) that reflects a stimulation of the reward system (RS). We consider that a magnesium-induced stimulation of the RS is an important issue for treating anhedonia in patients with MD. An increase of intracellular magnesium may be part of the mechanism of action of antidepressants.</description><identifier>ISSN: 0953-1424</identifier><identifier>EISSN: 1952-4021</identifier><identifier>DOI: 10.1684/mrh.2009.0177</identifier><identifier>PMID: 19780403</identifier><language>eng</language><publisher>Montrouge: John Libbey Eurotext</publisher><subject>Animals ; Antidepressive Agents - therapeutic use ; Biological and medical sciences ; Depressive Disorder, Major - drug therapy ; Erythrocytes - chemistry ; Feeding. Feeding behavior ; Fundamental and applied biological sciences. Psychology ; Humans ; Magnesium - blood ; Magnesium - therapeutic use ; Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><ispartof>Magnesium research, 2009-09, Vol.22 (3), p.163S-166S</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c290t-fa56b2dba191f70dd8f28fbf0b955015c01ca8fd15ed8b9535065439dbf8d7e33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23928,23929,25138,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21884935$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19780403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NECHIFOR, Mihai</creatorcontrib><title>Magnesium in major depression</title><title>Magnesium research</title><addtitle>Magnes Res</addtitle><description>There are contradictory data regarding the levels of magnesium in patients with major depression (MD) and how antidepressants influence their concentration. Our results show erythrocyte magnesium in patients with MD (44.39 +/- 2.7 mg/L vs. 59.1 +/- 3.2 mg/L in control group, p &lt; 0.05) and only in patients with severe MD (Hamilton score &gt; 23) was a moderate decrease in plasmatic magnesium observed (17.7 +/- 1.5 mg/L vs. 22.9 +/- 3.3 mg/L in control group). Therapy with antidepressants from different groups and with different mechanisms of action, such as amytriptiline (25 mg x 3/day per os, 4 weeks) and sertraline (50 mg x 3/day per os, 4 weeks) leads to a significant increase of magnesium concentration in erythrocytes (57.6 +/- 4.5 mg/L after amytriptiline, respectively 56.9 +/- 3.2 mg/L after sertraline, p &lt; 0.05 vs. before therapy). At the same time, in patients with MD, plasmatic levels of zinc were significantly decreased before therapy and increased after treatment with amytriptiline and sertraline (0.68 +/- 0.09 mg/L before treatment vs. 0.9 +/- 0.07 after amytriptiline). There is a positive correlation between concentrations of magnesium in erythrocytes and the clinical evolution of patients with MD. We consider that increasing intracellular concentration is a component of the antidepressant mechanism of sertraline and amytriptiline and maybe of other antidepressants. Anhedonia and autolytic tendencies are important elements of MD symptomatology. We tested the influence of MgCl2 0.2 mM/kg/day on a reward system using conditioned place preference (Panlab) in rats. Our data show a moderate stimulation of the reward system by magnesium (290.6 +/- 27 s time spent in a conditioned compartment before magnesium treatment and 363.3 +/- 16 s after magnesium treatment) that reflects a stimulation of the reward system (RS). We consider that a magnesium-induced stimulation of the RS is an important issue for treating anhedonia in patients with MD. An increase of intracellular magnesium may be part of the mechanism of action of antidepressants.</description><subject>Animals</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Erythrocytes - chemistry</subject><subject>Feeding. Feeding behavior</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Magnesium - blood</subject><subject>Magnesium - therapeutic use</subject><subject>Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><issn>0953-1424</issn><issn>1952-4021</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFz0tLw0AUhuFBFFurS5dKNi4Tz5lLMrOUUi9QcaPrMFdNaS7M2IX_3oQGXR04PHzwEnKNUGAp-X0bvwoKoArAqjohS1SC5hwonpIlKMFy5JQvyEVKOwAuaQXnZIGqksCBLcnNq_7sfGoObdZ0Wat3fcycH6JPqem7S3IW9D75q_muyMfj5n39nG_fnl7WD9vcUgXfedCiNNQZjQpDBc7JQGUwAYwSAlBYQKtlcCi8k-OPCSgFZ8qZIF3lGVuR_LhrY59S9KEeYtPq-FMj1FNmPWbWU2Y9ZY7-9uiHg2m9-9dz1wjuZqCT1fsQdWeb9OcoSskVE-wXbGhZ5w</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>NECHIFOR, Mihai</creator><general>John Libbey Eurotext</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20090901</creationdate><title>Magnesium in major depression</title><author>NECHIFOR, Mihai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c290t-fa56b2dba191f70dd8f28fbf0b955015c01ca8fd15ed8b9535065439dbf8d7e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Erythrocytes - chemistry</topic><topic>Feeding. Feeding behavior</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Magnesium - blood</topic><topic>Magnesium - therapeutic use</topic><topic>Vertebrates: anatomy and physiology, studies on body, several organs or systems</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NECHIFOR, Mihai</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Magnesium research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NECHIFOR, Mihai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Magnesium in major depression</atitle><jtitle>Magnesium research</jtitle><addtitle>Magnes Res</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>22</volume><issue>3</issue><spage>163S</spage><epage>166S</epage><pages>163S-166S</pages><issn>0953-1424</issn><eissn>1952-4021</eissn><abstract>There are contradictory data regarding the levels of magnesium in patients with major depression (MD) and how antidepressants influence their concentration. Our results show erythrocyte magnesium in patients with MD (44.39 +/- 2.7 mg/L vs. 59.1 +/- 3.2 mg/L in control group, p &lt; 0.05) and only in patients with severe MD (Hamilton score &gt; 23) was a moderate decrease in plasmatic magnesium observed (17.7 +/- 1.5 mg/L vs. 22.9 +/- 3.3 mg/L in control group). Therapy with antidepressants from different groups and with different mechanisms of action, such as amytriptiline (25 mg x 3/day per os, 4 weeks) and sertraline (50 mg x 3/day per os, 4 weeks) leads to a significant increase of magnesium concentration in erythrocytes (57.6 +/- 4.5 mg/L after amytriptiline, respectively 56.9 +/- 3.2 mg/L after sertraline, p &lt; 0.05 vs. before therapy). At the same time, in patients with MD, plasmatic levels of zinc were significantly decreased before therapy and increased after treatment with amytriptiline and sertraline (0.68 +/- 0.09 mg/L before treatment vs. 0.9 +/- 0.07 after amytriptiline). There is a positive correlation between concentrations of magnesium in erythrocytes and the clinical evolution of patients with MD. We consider that increasing intracellular concentration is a component of the antidepressant mechanism of sertraline and amytriptiline and maybe of other antidepressants. Anhedonia and autolytic tendencies are important elements of MD symptomatology. We tested the influence of MgCl2 0.2 mM/kg/day on a reward system using conditioned place preference (Panlab) in rats. Our data show a moderate stimulation of the reward system by magnesium (290.6 +/- 27 s time spent in a conditioned compartment before magnesium treatment and 363.3 +/- 16 s after magnesium treatment) that reflects a stimulation of the reward system (RS). We consider that a magnesium-induced stimulation of the RS is an important issue for treating anhedonia in patients with MD. An increase of intracellular magnesium may be part of the mechanism of action of antidepressants.</abstract><cop>Montrouge</cop><pub>John Libbey Eurotext</pub><pmid>19780403</pmid><doi>10.1684/mrh.2009.0177</doi></addata></record>
fulltext fulltext
identifier ISSN: 0953-1424
ispartof Magnesium research, 2009-09, Vol.22 (3), p.163S-166S
issn 0953-1424
1952-4021
language eng
recordid cdi_crossref_primary_10_1684_mrh_2009_0177
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Animals
Antidepressive Agents - therapeutic use
Biological and medical sciences
Depressive Disorder, Major - drug therapy
Erythrocytes - chemistry
Feeding. Feeding behavior
Fundamental and applied biological sciences. Psychology
Humans
Magnesium - blood
Magnesium - therapeutic use
Vertebrates: anatomy and physiology, studies on body, several organs or systems
title Magnesium in major depression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T02%3A28%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Magnesium%20in%20major%20depression&rft.jtitle=Magnesium%20research&rft.au=NECHIFOR,%20Mihai&rft.date=2009-09-01&rft.volume=22&rft.issue=3&rft.spage=163S&rft.epage=166S&rft.pages=163S-166S&rft.issn=0953-1424&rft.eissn=1952-4021&rft_id=info:doi/10.1684/mrh.2009.0177&rft_dat=%3Cpubmed_cross%3E19780403%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19780403&rfr_iscdi=true